Anzeige
Mehr »
Login
Sonntag, 23.03.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Breaking News: Syntheia meldet extremes User Wachstum: 10.000!!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W7D4 | ISIN: CA05156V1022 | Ticker-Symbol: IKAP
Tradegate
21.03.25
16:17 Uhr
7,740 Euro
-0,068
-0,87 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
AURINIA PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
AURINIA PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,7307,81022.03.
7,7307,88421.03.

Aktuelle News zur AURINIA PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.03.Medizinischer Leiter von Aurinia Pharmaceuticals verkauft Aktien im Wert von 68.350 US-Dollar5
05.03.Aurinia Pharmaceuticals stock climbs on insider buying4
27.02.Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations6
27.02.Aurinia Pharma reports mixed Q4 results; initiates FY25 outlook15
AURINIA PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.02.Aurinia Pharmaceuticals Inc. - 10-K, Annual Report3
27.02.Aurinia Pharmaceuticals Inc. - 8-K, Current Report1
08.11.24Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets15
07.11.24Aurinia stock jumps 14% on Q3 earnings, restructuring announcement13
07.11.24More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce3
07.11.24Aurinia Pharma GAAP EPS of $0.10 beats by $0.09, revenue of $67.77M beats by $10.08M6
07.11.24Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development178ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months...
► Artikel lesen
07.11.24Aurinia Pharmaceuticals Inc. - 10-Q, Quarterly Report-
07.11.24Aurinia Pharmaceuticals Inc. - 8-K, Current Report-
06.11.24Aurinia Pharma Q3 2024 Earnings Preview2
11.10.24Aurinia Pharmaceuticals spotlights lupus nephritis drug8
28.09.24Short Interest in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Declines By 13.0%3
24.09.24Aurinia Announces Approval Of LUPKYNIS In Japan8
24.09.24Japan approves Aurinia's lupus nephritis treatment1
13.08.24On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board397Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder...
► Artikel lesen
01.08.24Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results188ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the second quarter and six months...
► Artikel lesen
Seite:  Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1